全球多重检测市场：市场规模和占有率分析（依产品、类型和技术）、工业需求预测（截至 2030 年）

全球多重检测市场将以 9.0% 的复合年增长率成长，到 2023 年达到 39.18 亿美元，到 2030 年达到 71.035 亿美元。

其背景是慢性病和传染病的快速增加。 另一个关键因素是对研究和临床诊断中开发的分析平台的需求不断增长，以减少研究人员、患者和医疗保健提供者的成本。

依细分市场分析

依产品划分，消耗品类别在 2023 年以 45% 的占有率引领产业。 这是由于诊断测试数量的增加和生命科学公司研究活动的增加。

从技术角度来看，多重即时 PCR 类别将在未来几年内以 9.4% 的速度成长最快。 这是由于不同类型的 PCR 系统的快速可用性。

亚太地区成为成长最快的地区

由于医院数量不断增加、产业投资不断增加以及对已开发医疗基础设施的高需求，亚太地区正在以最快的速度发展。 中国也是该地区成长最快的国家。

北美将占据该行业的最大占有率，到2023年将占55%的占有率，并将在未来几年取得重大进展。 这是由于製药和生物技术公司为开发新药和诊断解决方案而增加的研发活动。

本报告分析了全球多重检测市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（以货币形式计算） ，2017-2030），依产品、类型和技术划分的详细趋势、市场竞争现状以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Abcam plc
• Becton, Dickinson and Company
• Merck KGaA
• Agilent Technologies Inc.
• Meso Scale Diagnostics LLC

第31章附录

The multiplex assays market was USD 3,918.0 million in 2023, which will reach USD 7,103.5 million, powering at a 9.0% CAGR, by 2030.

This is because of the surging incidence of chronic ailments as well as infectious diseases. Furthermore, the rising demand for developed analytical platforms in research and clinical diagnostics, to decrease the expenses for researchers, patients, and healthcare providers is also a key contributor.

According to the World Health Organization, chronic diseases including cancer, cardiovascular diseases, respiratory illnesses, and diabetes, will account for 86% of the 90 million deaths annually by around 2050, a significant increase of 90% since 2019.

Moreover, there were an estimated 249 million cases of malaria and 608,000 deaths from this disease in 85 nations in 2022. In addition, in the same year, there were around 39 million individuals with HIV globally. Of these, 1.5 million were children (below 15 years of age), and 37.5 million were adults. Additionally, 53% were girls and women.

The COVID-19 pandemic has had a positive impact on the industry, by driving an enormous rise in research & development for the production of innovative solutions to detect coronavirus.

Furthermore, the surging elderly population and incidence of autoimmune ailments, cancer, and human immunodeficiency virus are likely to drive the industry growth during this decade.

Segmentation Insights

The consumables category, based on product, led the industry in 2023, with a 45% share. This is because of the increasing count of diagnostic tests and the rising research activities by life sciences businesses.

For example, in January 2023, Novo Nordisk, a pharmaceutical firm, declared a grant of USD 6 million for Durham Technical Community College.

The grant is to assist the latter's life sciences program and build a new 35,000-square-foot training center.

In 2023, the protein-based category, based on type, accounted for the largest share, of 50%, owing to the rising adoption of such products in proteomics studies. Furthermore, protein-based assays are extensively employed in research to classify the concentration of electrophoresis, cell biology, protein, and various other analytes.

The multiplex real-time PCR category, based on technology, is likely to advance at the fastest rate, of 9.4%, in the years to come. This can be ascribed to the swift launch of different variants of PCR systems.

APAC is Fastest-Growing Region

APAC is advancing at the fastest rate, because of the increasing number of hospitals, rising investment value in this industry, and high requirement for developed healthcare infrastructure. In addition, China is the fastest-growing nation in APAC.

North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the years to come. This is because of the increasing research & development activities by pharmaceutical and biotechnology firms to develop new drugs as well as diagnostic solutions.

Competition Analysis

Key players are highly focused on investments and innovations to develop panels and devices for the multiplexed detection of the virus. Also, businesses are engaging in partnerships to distribute immunometric assays.

Oxford Nanopore Technologies and 10x Genomics, in October 2022, announced a partnership to develop an efficient workflow for full-length transcript sequencing in a single read on the devices of Oxford Nanopore.

This partnership enables the integration of Oxford's Promethlon devices as well as sample preparation on 10x Genomics devices, along with selected consumables.

With the surging incidence of infectious and chronic diseases, the multiplex assays industry will grow continuously in the coming years.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by technology
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Technology (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Technology (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Technology (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Technology (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Technology (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Technology (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Technology (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Technology (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Technology (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Technology (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Technology (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Technology (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Technology (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Technology (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Technology (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Technology (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Technology (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Technology (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Technology (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Technology (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Technology (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Technology (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Technology (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Illumina Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Bio-Rad Laboratories Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Qiagen N.V.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abcam plc
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Becton, Dickinson and Company
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Merck KGaA
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Agilent Technologies Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Meso Scale Diagnostics LLC
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports